Co-Diagnostics Statistics
Total Valuation
Co-Diagnostics has a market cap or net worth of $33.21 million. The enterprise value is -$2.09 million.
Important Dates
The last earnings date was Thursday, November 7, 2024, after market close.
Earnings Date | Nov 7, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Co-Diagnostics has 31.93 million shares outstanding. The number of shares has increased by 2.06% in one year.
Current Share Class | 31.93M |
Shares Outstanding | 31.93M |
Shares Change (YoY) | +2.06% |
Shares Change (QoQ) | +1.23% |
Owned by Insiders (%) | 5.40% |
Owned by Institutions (%) | 14.05% |
Float | 30.21M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 4.26 |
Forward PS | 86.82 |
PB Ratio | 0.52 |
P/TBV Ratio | 0.88 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.92, with a Debt / Equity ratio of 0.04.
Current Ratio | 6.92 |
Quick Ratio | 6.53 |
Debt / Equity | 0.04 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -50.57% and return on invested capital (ROIC) is -29.64%.
Return on Equity (ROE) | -50.57% |
Return on Assets (ROA) | -27.61% |
Return on Capital (ROIC) | -29.64% |
Revenue Per Employee | $47,232 |
Profits Per Employee | -$266,350 |
Employee Count | 155 |
Asset Turnover | 0.08 |
Inventory Turnover | 1.28 |
Taxes
In the past 12 months, Co-Diagnostics has paid $3.90 million in taxes.
Income Tax | 3.90M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.64% in the last 52 weeks. The beta is -0.85, so Co-Diagnostics's price volatility has been lower than the market average.
Beta (5Y) | -0.85 |
52-Week Price Change | -24.64% |
50-Day Moving Average | 1.22 |
200-Day Moving Average | 1.22 |
Relative Strength Index (RSI) | 30.65 |
Average Volume (20 Days) | 90,878 |
Short Selling Information
The latest short interest is 208,704, so 0.65% of the outstanding shares have been sold short.
Short Interest | 208,704 |
Short Previous Month | 226,426 |
Short % of Shares Out | 0.65% |
Short % of Float | 0.69% |
Short Ratio (days to cover) | 2.63 |
Income Statement
In the last 12 months, Co-Diagnostics had revenue of $7.32 million and -$41.28 million in losses. Loss per share was -$1.38.
Revenue | 7.32M |
Gross Profit | 3.61M |
Operating Income | -40.00M |
Pretax Income | -35.81M |
Net Income | -41.28M |
EBITDA | -38.67M |
EBIT | -40.00M |
Loss Per Share | -$1.38 |
Full Income Statement Balance Sheet
The company has $37.66 million in cash and $2.37 million in debt, giving a net cash position of $35.29 million or $1.11 per share.
Cash & Cash Equivalents | 37.66M |
Total Debt | 2.37M |
Net Cash | 35.29M |
Net Cash Per Share | $1.11 |
Equity (Book Value) | 63.78M |
Book Value Per Share | 2.00 |
Working Capital | 34.31M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$25.70 million and capital expenditures -$1.14 million, giving a free cash flow of -$26.84 million.
Operating Cash Flow | -25.70M |
Capital Expenditures | -1.14M |
Free Cash Flow | -26.84M |
FCF Per Share | -$0.84 |
Full Cash Flow Statement Margins
Gross Margin | 49.30% |
Operating Margin | -546.37% |
Pretax Margin | -510.65% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -287.51% |
Dividends & Yields
Co-Diagnostics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -2.06% |
Shareholder Yield | -2.06% |
Earnings Yield | -124.32% |
FCF Yield | -80.83% |
Analyst Forecast
The average price target for Co-Diagnostics is $1.50, which is 44.23% higher than the current price. The consensus rating is "Hold".
Price Target | $1.50 |
Price Target Difference | 44.23% |
Analyst Consensus | Hold |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Co-Diagnostics has an Altman Z-Score of 1.07 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.07 |
Piotroski F-Score | 2 |